Squarepoint
GLUE icon

Squarepoint’s Monte Rosa Therapeutics GLUE Stock Holding History

Squarepoint’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Buy
82,953
+45,846
+124% +$866K ﹤0.01% 2345
2026
Q1 		$610K Buy
37,107
+27,078
+270% +$518K ﹤0.01% 3176
2025
Q4 		$157K Sell
10,029
-84,678
-89% -$1.14M ﹤0.01% 3938
2025
Q3 		$702K Sell
94,707
-83,429
-47% -$442K ﹤0.01% 2948
2025
Q2 		$803K Buy
+178,136
New +$795K ﹤0.01% 2859
2025
Q1 		– Sell
-31,654
Closed -$220K – 4891
2024
Q4 		$220K Buy
+31,654
New +$238K ﹤0.01% 4397
2024
Q3 		– Sell
-22,665
Closed -$84.8K – 4316
2024
Q2 		$84.8K Buy
+22,665
New +$116K ﹤0.01% 3825
2024
Q1 		– Sell
-17,462
Closed -$98.7K – 4224
2023
Q4 		$98.7K Buy
+17,462
New +$68.5K ﹤0.01% 3756
2023
Q2 		– Sell
-13,998
Closed -$109K – 3720
2023
Q1 		$109K Buy
+13,998
New +$97.3K ﹤0.01% 2956
2022
Q4 		– Sell
-28,410
Closed -$232K – 3331
2022
Q3 		$232K Buy
28,410
+13,108
+86% +$120K ﹤0.01% 2622
2022
Q2 		$148K Buy
+15,302
New +$154K ﹤0.01% 2552
2021
Q3 		– Sell
-28,209
Closed -$640K – 3096
2021
Q2 		$640K Buy
+28,209
New +$575K ﹤0.01% 1962

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's GLUE Position: Q2 2026 in Review

Squarepoint increased its Monte Rosa Therapeutics (GLUE) stake by 124% in Q2 2026, buying an estimated $866K and bringing the position to 82,953 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2345.

Squarepoint first reported a position in GLUE in Q2 2021 and has held it in 12 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Squarepoint held 82,953 shares of Monte Rosa Therapeutics worth $2.01M as of Q2 2026.
  • Squarepoint bought 45,846 Monte Rosa Therapeutics shares in Q2 2026, an estimated $866K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2345 holding.
  • Squarepoint first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.